The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Safety of Rituximab Compared with Steroids and Cyclophosphamide for Idiopathic Membranous Nephropathy
Open accessAbstract
Guidelines recommend steroid plus cyclical cyclophosphamide (S t-C p) therapy for patients with idiopathic membranous nephropathy at high risk of progression to ESRD. Rituximab (R tx) may be a safer alternative. In this retrospective, observational cohort study, we compared time to any adverse event (primary outcome); serious or nonserious events; partial and complete remission of the nephrotic syndrome; and a composite of doubling of serum creatinine, ESRD, or death between 100 R tx-treated patients and 103 patients who received daily S t-C p. We monitored patients with standardized protocols and adjusted for baseline characteristics by Cox regression. Over a median follow-up of 40 months, the R tx group had significantly fewer adverse events than the S t-C p group (63 versus 173;P<0.001), both serious (11 versus 46;P<0.001) and nonserious (52 versus 127;P<0.001). Cumulative incidence of any first (35.5% versus 69.0%;P<0.001), serious (16.4% versus 30.2%;P=0.002), or nonserious (23.6% versus 60.8%;P<0.001) event was significantly lower with R tx. Adjusted hazard ratios (95% confidence intervals) between R tx and S t-C p groups were 0.27 (0.16 to 0.44) for any first adverse event, 0.32 (0.15 to 0.68) for serious adverse events, and 0.23 (0.13 to 0.41) for nonserious adverse events. Although the cumulative incidence of partial remission was lower in the R tx group, rates of complete remission and the composite renal end point did not differ significantly between groups. Because of its superior safety profile, we suggest that R tx might replace S t-C p as first-line immunosuppressive therapy in patients with idiopathic membranous nephropathy and nephrotic syndrome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Evaluating medication effects outside of clinical trials: new-user designs
Ray, W. A. (2003) · American Journal of Epidemiology · doi:10.1093/aje/kwg231 · Cited by 1,646
Observational research, randomised trials, and two views of medical science
Vandenbroucke, J. P. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050067 · Cited by 416
Cited by
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
Rovin, B. H., Adler, S. G., Barratt, J., Bridoux, F., Burdge, K. A., Chan, T. M., Cook, H. T., Fervenza, F. C., Gibson, K. L., Glassock, R. J., et al. (2021) · Kidney International · doi:10.1016/j.kint.2021.05.021 · Cited by 2,518
Self-citationKalantar-Zadeh, K., Jafar, T. H., Nitsch, D., Neuen, B. L., & Perkovic, V. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00519-5 · Cited by 1,461
Floege, J., Barbour, S. J., Cattran, D. C., Hogan, J. J., Nachman, P. H., Tang, S. C. W., Wetzels, J. F. M., Cheung, M., Wheeler, D. C., Winkelmayer, W. C., et al. (2019) · Kidney International · doi:10.1016/j.kint.2018.10.018 · Cited by 263
“matched cohort study suggested lower partial remission rates with rituximab versus cyclophosphamide.(110) Measurement of PLA2R antibodies might aid in predicting treatment response (Table 3).”
ResultSelf-citation
Metadata
- Authors
- van den Brand, J. A. J. G., Ruggenenti, P., Chianca, A., Hofstra, J. M., Perna, A., Ruggiero, B., Wetzels, J. F. M., & Remuzzi, G.
- Venue
- Journal of the American Society of Nephrology
- Published
- 2017-05-09
- Volume
- 28
- Issue
- 9
- Pages
- 2729-2737
- ISSN
- 1046-6673 (ISSN-L)
- 1533-3450
- OpenAlex
- W2613205117
- Cited by
- 188
- References
- 2
- FWCI
- 10.29
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety of Rituximab Compared with Steroids and Cyclophosphamide for Idiopathic Membranous Nephropathy. https://app.cochat.ai/papers/10.1681/asn.2016091022
- The paper
- van den Brand, J. A. J. G., Ruggenenti, P., Chianca, A., Hofstra, J. M., Perna, A., Ruggiero, B., Wetzels, J. F. M., & Remuzzi, G. (2017). Safety of Rituximab Compared with Steroids and Cyclophosphamide for Idiopathic Membranous Nephropathy. Journal of the American Society of Nephrology. https://doi.org/10.1681/asn.2016091022
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.